Skip to main content

Moderna Value Stock - Dividend - Research Selection

Moderna, Inc

ISIN: US60770K1079, WKN: A2N9D9

Market price date: 23.07.2021
Market price: 348,83 USD




Moderna, Inc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 10-03-2021
Cash flow
Net operating cash flow 2.026.970.000
Capital Expenditures -67.448.000
Free cash flow 1.959.522.048
Balance sheet
Total Equity 2.561.370.000
Liabilities & Shareholders equity 7.336.750.000
Income statement
Net income -747.064.000
Eps (diluted) -1,960
Diluted shares outstanding 381.000.000
Net sales/revenue 803.395.000

Fundamental ratios calculated on: 23-07-2021

Ratios
Key figures 23-07-2021
Cash flow
P/C 65,57
   
P/FC 67,83
Balance sheet
ROI-10,18
ROE34,91
Income statement
P/E-177,97
Div. Yield0,00%
P/B51,89
P/S165,43


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolMRNA
Market Capitalization132.904.230.912,00 USD
Country
IndicesNO INDEX
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.modernatx.com


Description of the company

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.modernatx.com